A beyond-use date, commonly abbreviated BUD, marks the point at which a compounded medication is no longer considered appropriate for use. It is distinct from the expiration date printed on a commercially manufactured product, which is based on formal, longer-term stability testing by the manufacturer. Because compounded preparations are made in smaller batches under varying conditions, their BUDs are typically much shorter and are determined using a different set of considerations, including the type of preparation, the ingredients involved, and how it is stored and packaged.
Compounding standards provide general frameworks pharmacists use to reason about appropriate BUD assignment for sterile and non-sterile preparations, though the specific date assigned depends on the characteristics of each individual preparation.
Why it matters
Assigning an appropriate beyond-use date is a routine but consequential part of compounding practice — a date set incorrectly can mean a patient receives a preparation that has degraded, or a pharmacy discards usable product unnecessarily. Inspectors reviewing compounding operations commonly check BUD documentation and the reasoning behind it, so pharmacists involved in compounding need to be comfortable explaining how a given BUD was determined. This concept connects closely to the compounding category a facility operates under and the sterile or non-sterile standards it follows.
RxByState tracks how compounding-related requirements and inspection expectations vary by state. Learn more at https://app.rxbystate.com/signup.